: iStockAnalyst.com Symbols Feed

November 5, 2008: Clean Up When Funds Clear Out

Wed, 05 Nov 2008 21:50:00 GMT

Money managers clean up portfolio holdings before the end of their tax year. Over 48%of US mutual funds close their books between late October and December. Managers sell stocks with large losses to avoid reporting them on their year-end report to shareholders. This causes downward pressure on stocks trading within their portfolio(s)that are at or near 52-week lows. Once the selling subsides, these stocks have historically experienced a price reversal. That said, investors should exercise due diligence before buying any of the companies listed below by analyzing any potential shift in a company's fundamentals and other factors such as sector weight and risk tolerance. Here are the screen parameters used to select the following "sells" from funds: Large-cap and mid-cap stocks trading at or below 30% of their 52-week high and have not bounced above 15% from their 52-week low,and have above-average valuation on both an absolute and[More...]

Analyst Comments: Deutsche Bank, Acxiom, Amdocs, Chesapeake, Onyx Pharmaceuticals

Thu, 07 Aug 2008 05:47:00 GMT

We are continuing our Hold on Deutsche Bank AG (DB). DB posted second quarter earnings before nonrecurring items of 418 million, down 75% from the year-ago quarter, but up sequentially from a 985 million loss in the first quarter.[More...]

Few Thoughts and a Look at the Earnings in the Coming Week

Mon, 28 Jul 2008 05:15:00 GMT

WITH RESPECT TO THE US’ GDP GROWTH, THE NATIONAL BUREAU OF ECONOMIC RESEARCH SEES A SIGNIFICANT DECLINE IN ECONOMIC ACTITIVY SPREAD ACROSS THE ECONOMY, WHICH WILL LAST MORE THAN A FEW MONTHS - WSJ - According to Robert Hall, economist at Stanford University, US economic data that has been reported provide (...)[More...]

Analyst Comments: OSI Pharma, Intevac, Acxiom, ATS Medical

Fri, 30 May 2008 06:58:21 GMT

We upgrade OSI Pharmaceuticals, Inc. (OSIP) to Buy from Hold, as we expect the biotechnology company to achieve sustainable growth in the next few years. While strong sales of its primary product -- cancer drug Tarceva -- continues to impress, we are optimistic of the revenue potential from the company's DPP-IV diabetes drug patent estate. Despite the decision of the European Patent Office to revoke one of the company's European patents, we do not...[More...]

Analyst Comments:Acxiom, Avis, Agrium, Avnet, CarMax, Morton's Restaurant, LeapFrog, Duke Realty

Fri, 04 Apr 2008 18:09:59 GMT

We continue to rate Acxiom Corporation (ACXM) a Hold with a target price of $12. Management's guidance for fiscal 2008 remains lackluster and essentially suspended long-term financial guidance due to lack of visibility. Revenues are expected to be flat or down 1% compared to fiscal year 2007 while EPS, before any one-time...[More...]

NASDAQ Technical Picture - Tech Provides Leadership

Fri, 15 Feb 2008 12:22:32 GMT

Tech provided leadership on the heels of better earnings from Semi +3% (AMAT +10.1%) which carried over to othe[More...]

Paperstand (NOK to acquire NVT; ACXM deal goes bust; UBS sees loss)

Mon, 01 Oct 2007 14:02:48 GMT

Accordingt to the WSJ, Nokia (NOK) last night was deep in discussions to purchase Navteq (NVT), marking what would be one of its largest-ever corporate acquisitions. With a $7.61bn mkt cap, Navteq is one of the world's leaders in electronic mapping, which enables in-vehicle navigation devices and a new generation of mobile-phone applications used...[More...]

Acxiom Names Two New Directors

Tue, 25 Aug 2009 13:48:00 GMT

Acxiom Corporation, a US-based provider of interactive marketing solutions, has named Jerry Gramaglia and Clark Kokich to its board of directors.
Mr Gramaglia began his career at Procter and Gamble and later held senior marketing and general management positions for Nestle, PepsiCo, Imasco and Sprint.
Mr Kokich is chairman of the board of consultancy firm Razorfish.

: iStockAnalyst.com Symbols Feed

November 5, 2008: Clean Up When Funds Clear Out

Analyst Comments: Deutsche Bank, Acxiom, Amdocs, Chesapeake, Onyx Pharmaceuticals

Few Thoughts and a Look at the Earnings in the Coming Week

Analyst Comments: OSI Pharma, Intevac, Acxiom, ATS Medical

Analyst Comments:Acxiom, Avis, Agrium, Avnet, CarMax, Morton's Restaurant, LeapFrog, Duke Realty

NASDAQ Technical Picture - Tech Provides Leadership

Paperstand (NOK to acquire NVT; ACXM deal goes bust; UBS sees loss)

Acxiom Names Two New Directors

Net Ads Becoming More Personal

Acxiom Returns to Profit

Recession's Effects on Arkansas' Public Companies Prove Mixed

Acxiom Posts Loss

Consumers Get Frugal, so Retailers Get Creative

Advisers to Investors: Keep Calm to Cash In On Eventual Recovery

Acxiom Acquires Alvion Direct Marketing Unit

Acxiom Highlights Dramatic Expansion of Advertising Solutions at ad:tech New York

Online Consumers Stand to Benefit From Joint Acxiom-Kynetx Solutions

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on AIS, AMG, WAT, ALK, ALTU and ACXM

Insight Into Committed Online Shoppers Creates World of Opportunity

Acxiom Study Reveals Insights for Squeezing Extra Mileage from “Cash for Clunkers” Program

Acxiom Honored for Outstanding Contributions to Marketing

Acxiom Announces First Quarter Fiscal Year 2010 Results

CA Message Manager Chosen by LPL Financial for Superior Email Supervision, Recognizing $1M Savings a Year

CA and Acxiom Announce Partnership to Provide Cloud-Delivered Information Governance Solution

Acxiom Teams Up with Independent Thought Leaders for Global Marketing Performance Series

Form 4 WISE R HALSEY For: Sep 01 (10K)

Form 4 TWOMEY KEVIN M For: Sep 01 (10K)

Form 4 MCLARTY THOMAS F III For: Sep 01 (10K)

Form 4 Gramaglia Jerry For: Sep 01 (10K)

Form 4 GOOD MARY L For: Sep 01 (10K)

Form 4 ACXIOM CORP For: Sep 01 Filed by: KOKICH CLARK M (10K)

Form 4 DURHAM MICHAEL J For: Sep 01 (10K)

Form 4 DILLARD WILLIAM T II For: Sep 01 (10K)

Form 4 JONES JERRY C For: Sep 02 (10K)

Form 4 CHILDERS CINDY K For: Jul 01 (10K)